• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • QED-C
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Case study September 3, 2019

Automating chemical drug discovery and synthesis

SRI International’s continuous flow SynFini™ Suite produced multiple nucleoside antivirals in a single day


Challenge/Goal

Synthetic chemistry has greatly enhanced our health and well-being over the past two centuries, generating thousands of new medicines, agricultural compounds and industrial chemicals. Over this time however, the laboratory methods used to synthesize compounds have changed very little: They are still highly manual, frustratingly slow, and difficult to reproduce and scale. Automating these processes would expand availability of key compounds – including commonly used medications – while freeing chemists to focus on the next generation of life-enhancing molecules.

Solution/Outcome

SRI developed a proprietary synthetic chemistry platform, the SynFini™ Suite, to automate the route design and synthesis of small molecule drug-like compounds. Using known procedures and machine learning, this multi-step, continuous suite of tools has demonstrated ability to dramatically streamline the chemical drug discovery and production process. SRI scientists recently used the SynFini platform to synthesize the nucleoside antivirals ribavirin, taribavirin, and tiazofurin consecutively over a 13-hour period, producing hundreds of milligrams of each product with no minimal manual intervention.

The SynFini Suite consists of three integrated components – SynRoute ™, SynJet™ and AutoSyn™ – that automatically design synthetic routes for molecules of interest, conduct subsequent reaction screening and optimization, and then produce the selected molecules on scales from micrograms to kilograms.

To synthesize ribavirin, taribavirin and tiazolfurin, SRI scientists first used SynRoute to propose synthesis strategies for producing ribavirin and its analogues in a flow chemistry format. They then performed an optimization study of the first step of ribavirin on SynJet, which helped determine the operating parameters for the continuous flow synthesis.

Finally, researchers developed the complete multistep synthetic procedure on AutoSyn, using it as a template for the synthesis of taribavirin, and demonstrated the SynRoute strategy for the three-step synthesis of tiazofurin. All three drugs were successfully synthesized in a 13-hour period – less than about a tenth of the time that is required to produce the same quantities of these drugs through manual chemical processes.

Share this

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2022 SRI International